Natco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins and lower annual earnings weighed on investor sentiment despite a one-time tax-related benefit recorded during the quarter and full financial year.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.